DONATE

IBEC and ICMS reunite once more at their Annual Collaborative Symposium

Today, on March 14th, the joint ICMS-IBEC symposium took place. This event was co-organized by IBEC and the Institute for Complex Molecular Systems (ICMS). Throughout the conference, researchers from both IBEC and ICMS presented their areas of research, aiming to enhance the scientific collaboration between the two institutions.

IBEC and AEFAT join forces against ataxia telangiectasia

Today, the event “Advances in Ataxia Telangiectasia” took place, organized by the Institute of Bioengineering of Catalonia (IBEC) in collaboration with AEFAT, the Spanish ataxia-telangiectasia family association. The gathering brought together patients’ families, researchers, and clinicians to explore the latest advancements in the clinical management of ataxia telangiectasia.

Nanomedicine to tackle rare diseases

Experts in nanomedicine from various fields have gathered today for the fifth consecutive year at Nano Rare Diseases Day. This event is co-organized by the NANOMED Spain platform, coordinated by IBEC, and SJD Barcelona Children’s Hospital, showcasing the latest advances in nanomedicine for the diagnosis and treatment of rare diseases.

IBEC Drives Dialogue on Innovations in Personalized Medicine and Emerging Therapies at Barcelona Health Innovation Week

Today, on February 14, IBEC organized the roundtable “Challenges in Innovation in Personalized Medicine and Emerging Therapies.” The event is part of Barcelona Health Innovation Week, organized by Biocat. It fostered a dialogue where experts from diverse fields shared their perspectives on identifying opportunities to propel the utilization of new technologies in the healthcare sector.

Nanomedicine experts gather on World Cancer Nanoday

Once again, experts in nanomedicine from various fields gathered in Barcelona on the occasion of World Cancer Day. The meeting provided an opportunity to showcase the latest innovations in nanomedicine for combating cancer, covering topics such as early diagnosis, controlled drug release, and radiotherapy employing nanoparticles.

IBEC is strengthened by the addition of three new research groups in advanced and emerging therapies

IBEC kicks off 2024 with the incorporation of three new research groups led by Manuel Salmerón Sánchez, Zaida Álvarez Pinto, and Xavier Rovira Clavé. With these additions, IBEC strengthens its position in the field of advanced and emerging therapies.

Organoids to study ataxia telangiectasia

Núria Montserrat Pulido, principal investigator at IBEC, will lead a project to study Ataxia telangiectasia thanks to funding from AEFAT, the Spanish ataxia-telangiectasia family association. The idea of the project is to obtain cells with the patient mutations, develop organoids, explore the possibility of gene editing processes for different mutations and create a platform for drug testing.